Instrumentation Laboratory to Directly Distribute Hemostasis Product Line in North America
17 May 2012
Instrumentation Laboratory (IL) has announced that its Strategic Alliance Cross-Distribution agreement with Beckman Coulter will terminate on June 22, 2012, after more than twenty successful years.
From June 23, 2012, IL will initiate direct sales, service, support and marketing to end-user customers in the U.S. and Canada. This service will cover their Hemostasis product line, including including the HemosIL® line of reagents, ACL TOP® Family of Hemostasis Testing Systems, ACL ELITE®/ELITE PRO analyzers and other ACL® systems.
IL hope that the transition will allow the company to respond quickly to changing needs, continuously impove the quality of their products and services, expedite innovation to Hemostasis labs, and reduce complexity of operations.
“IL has achieved significant growth in Hemostasis, culminating in the attainment of the number one market share position worldwide, thanks to our focus on quality and innovation,” said Ramon Benet, CEO at IL. “Now is the ideal time for us to apply our expertise, resources, and world-class service organization to working directly with our Hemostasis customers in North America, and focus on ensuring a smooth transition for our customers.”
“We have incredibly strong relationships with our customers in Critical Care testing, because our direct sales, service and support groups are second to none,” said Brian Durkin, Vice President, Commercial Operations, North America at IL. “I am certain that we will forge similar partnerships with our Hemostasis customers, providing them outstanding support, and an uninterrupted workflow in their laboratories during this transition.”
IL will honor all customer contracts, including end-user and Group Purchasing Organization agreements. All current pricing, terms and conditions will remain in effect through the term of any existing agreement.